دورية أكاديمية
β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy
| العنوان: | β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy |
|---|---|
| المؤلفون: | Sturm, Gunter Johannes, Herzog, Sereina, Aberer, Werner, Alfaya Arias, Teresa, Antolin-Amerigo, Dario, Bonadonna, Patrizia, Boni, Elisa, Bozek, Andrzej, Chelminska, Marta, Ernst, Barbara, Frelih, Nina, Gawlik, Radoslaw, Gelincik, Asli, Hawranek, Thomas, Hoetzenecker, Wolfram, Jimenez Blanco, Aranzazu, Kita, Karolina, Kendirlinan, Resat, Kosnik, Mitja, Laipold, Karin, Lang, Roland, Marchi, Francesco, Mauro, Marina, Nittner-Marszalska, Marita, Poziomkowska-Gesicka, Iwona, Pravettoni, Valerio, Preziosi, Donatella, Quercia, Oliviero, Reider, Norbert, Rosiek-Biegus, Marta, Ruiz-Leon, Berta, Schrautzer, Christoph, Serrano, Pilar, Sin, Aytul, Sin, Betul Ayse, Stoevesandt, Johanna, Trautmann, Axel, Vachova, Martina, Arzt-Gradwohl, Lisa |
| المصدر: | 0105-4538 ; Allergy: European journal of allergy and clinical immunology |
| سنة النشر: | 2021 |
| المجموعة: | IRUA - Institutional Repository van de Universiteit Antwerpen |
| مصطلحات موضوعية: | Human medicine |
| الوصف: | Background There is controversy whether taking beta-blockers or ACE inhibitors (ACEI) is a risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the number or severity of adverse events (AE) during venom immunotherapy (VIT). Methods In this open, prospective, observational, multicenter trial, we recruited patients with a history of a SSR and indication for VIT. The primary objective of this study was to evaluate whether patients taking beta-blockers or ACEI show more systemic AE during VIT compared to patients without such treatment. Results In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Of all patients included, 388 (27.2%) took antihypertensive (AHT) drugs (10.4% took beta-blockers, 11.9% ACEI, 5.0% beta-blockers and ACEI). Only 5.6% of patients under AHT treatment experienced systemic AE during VIT as compared with 7.4% of patients without these drugs (OR: 0.74, 95% CI: 0.43-1.22, p = 0.25). The severity of the initial sting reaction was not affected by the intake of beta-blockers or ACEI (OR: 1.14, 95% CI: 0.89-1.46, p = 0.29). In total, 210 (17.7%) patients were re-stung during VIT and 191 (91.0%) tolerated the sting without systemic symptoms. Of the 19 patients with VIT treatment failure, 4 took beta-blockers, none an ACEI. Conclusions This trial provides robust evidence that taking beta-blockers or ACEI does neither increase the frequency of systemic AE during VIT nor aggravate SSR. Moreover, results suggest that these drugs do not impair effectiveness of VIT. (Funded by Medical University of Graz, Austria; Clinicaltrials.gov number, NCT04269629). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/isi/000627700100001 |
| الإتاحة: | https://doi.org/10.1111/ALL.14785Test https://hdl.handle.net/10067/1775470151162165141Test https://repository.uantwerpen.be/docstore/d:irua:5977Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.40474458 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |